Literature DB >> 6609768

Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects.

J A Straw, D Szapary, W T Wynn.   

Abstract

After i.v. administration of d,l-, 1-5-formyltetrahydrofolate (d,l-CHO-THF) CHO-THF was rapidly cleared from the plasma by conversion to 5-methyltetrahydrofolate (5-CH3-THF) and urinary excretion, whereas d-CHO-THF, which was not metabolized and was slowly excreted in the urine, persisted in plasma at concentrations greatly exceeding those of l-CHO-THF and 5-CH3-THF. The plasma half-life (beta) of the unnatural (d) isomer was 451 +/- 24 (S.E.) min compared to 31.6 +/- 1.1 min for the natural (l) isomer, and 227 +/- 20 min for its active metabolite, 5-CH3-THF. The half-lives and volumes of distribution of each of the three compounds were independent of dose over a range of 25 to 100 mg, indicating that mechanisms for distribution, metabolism, and excretion are not saturable over the dose range tested. The urinary clearance of l-CHO-THF or 5-CH3-THF differed only slightly from creatinine clearance, whereas urinary clearance of d-CHO-THF was only one-fifth creatinine clearance, indicating that d-CHO-THF was extensively reabsorbed. Absorption of d,l-CHO-THF after p.o. administration was stereoselective in that absorption of the l-isomer was approximately 5 times that of the d isomer. Thus, p.o. administration resulted in a more favorable ratio of active to inactive folates in plasma. At a dose of 25 mg, absorption approached 100% for l-CHO-THF compared to 20% for d-CHO-THF. However, absorption was saturable, and lower percentages of both compounds were absorbed at doses of 50 and 100 mg.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609768

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Inhibition of thymidylate synthase by the diastereoisomers of leucovorin.

Authors:  P P Lee; R L Schilsky
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro.

Authors:  Michele Visentin; Ersin Selcuk Unal; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-29       Impact factor: 3.333

3.  Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.

Authors:  C Wolfrom; R Hepp; R Hartmann; H Breithaupt; G Henze
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid.

Authors:  A Schalhorn; M Kühl; G Stupp-Poutot; V Nüssler
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study.

Authors:  Yani Liu; Jiali Zhou; Zhongfang Li; Chunxiao Yang; Jianhong Wu; Yu Zhang; Shaojun Shi; Yunqiao Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-08-31       Impact factor: 2.441

6.  Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate.

Authors:  P O Greiner; J Zittoun; J Marquet; J M Cheron
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

7.  Accumulation of tetrahydrofolates in human plasma after leucovorin administration.

Authors:  M A Bunni; B M Rembiesa; D G Priest; E Sahovic; R Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Pharmacokinetic comparison of leucovorin and levoleucovorin.

Authors:  J Zittoun; A P Tonelli; J Marquet; E De Gialluly; C Hancock; A Yacobi; J B Johnson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance.

Authors:  F M Muggia; A Tulpule; A Retzios; F Chen; S Jeffers; C G Leichman; L Leichman; C P Spears; K K Chan
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

10.  A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.

Authors:  Marie-Christine Etienne-Grimaldi; Eric François; Jean-Michel Cardot; Nicole Renée; Jean-Yves Douillard; Erick Gamelin; Jaafar Bennouna; Yann Château; Gérard Milano
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.